The relevance of p53 mutation in urological malignancies: Possible clinical implications for bladder cancer

British Journal of Urology

Volumn 78, Issue 3, 1996, Pages 337-344

  Nouri, A M E ^a,b   Darakhshan, F ^b   Cannell, H ^a   Paris, A M I ^a   Oliver, R T D ^a  

^a Whittington Health   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; CISPLATIN; DNA; ETOPOSIDE; HEAT SHOCK PROTEIN; MITOMYCIN C; PROTEIN P53;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER SURVIVAL; CELL DIVISION; CHROMOSOME 17Q; DNA REPAIR; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; URINARY TRACT CANCER;

EID: 0030435996     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.00085.x     Document Type: Article

References (53)

1. Lane DP, Crawford LV. Protein synthesis required to anchor a mutant p53 protein which is temperature sensitive for nuclear transport. Nature 1979; 278: 261-3
2. Harris A, Smith K, Neal D, Fenneley J, Hall R. Epidermal growth factor expression correlates with tumour recurrence, stage progression and overall survival in human bladder cancer. Proc Am Assoc Cancer Res 1988; 29: 453-8
3. Nouri AME, Dos Santos AVL, Crosby D, Oliver RTD. Correlation between class I antigen expression and the ability to generate tumour infiltrating lymphocytes from bladder tumour biopsies. Br }Cancer 1991; 64: 996-1000
4. Nouri AME, Hussain RF, Oliver RTD. The frequency of MHC antigen abnormalities in urological tumours and their correction by gene transfection or cytokine stimulation. Gene Therapy 1994; 1: 119-23
5. Oliver RTD, Nouri AME. T cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Survey 1991; 13: 173-204
6. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64: 235-48
7. Levine AJ. The tumor suppressor genes. Ann Rev Biochem 1993; 62: 523-51
8. Donehower LA, Harvey M, Stagle BL et al Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 365: 215-21
9. Alberts JJ, The Molecular Biology of the Cell. 3rd edn. New York. Garland, 1994: 1281-9
10. Rotter V, Prokocimer M. p53 and human malignancies. Adv Cancer Res 1991; 57: 257-70
11. Marx J. How p53 suppresses cell growth. Science 1993; 262: 1644-5
12. Cannon JV, Lane DP. Protein sythesis required to anchor a mutant p53 protein which is temperature sensitive for nuclear transport. Nature 1991; 349: 802-6
13. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352: 345-7
14. Arenas MJ, Wyllie AH. Apoptosis, mechanisms and roles in pathology. M Rev Pathol 1991; 32: 223-54
15. Hollstein M, Sidraisker D, Vogelstein B. Harris CC. p53 mutations in human cancers. Science 1991: 253: 49-53
16. Marshall CJ. p53 tumor suppressor genes. Cell 1991: 64: 313-26
17. Harris C. p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 1993: 262: 1980-1
18. Shaw PBR. Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild type p53 in a human colon tumour derived cell line. Pror Natl Acad Sci 1992: 40: 4495-9
19. Liu T], Zhang WW, Taylor DL, Roth JA, Goepert H. dayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-7
20. Kayo E. Yokozaki H. Yanagihara K et al Reduced tumorigenicity and cell motility of a genetic-carcinoma cell-line by introduction of wild- type p53 gene. Int }Oncol 1993; 2: 265-71
21. Watanabe ER, Tomita Y. Nishiyama T, Tanikawa T, Sato SS. Correlation of p53 protein expression in human urothelial transitional cell cancers with malignant potential and patient survival. Int ] Urol 1994: 1: 43-8
22. Kuczyk M. Serth J. Bokemeyer C et al. Value of the proliferation status (PCNA) and p5 3 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder. Urologe Ausgabe 1995; 34: 146-52
23. Moch H, Sauter G, Mihatsch M. Gudat F, Epper R. Waldman F. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 1994; 25: 1346-51
24. Schmitz-Drager B, van Roeyen C. Grimm M et al. P53 acumulation in precursor lesions and early stages of bladder cancer. World J Urol 1994; 12: 79-83
25. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl J Med 1994; 331: 1259-64
26. Sarkis A. Bajorin D. Reuter V et al Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384-90
27. Peck R. Bollag W. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Cancer 1968: 27: 53-7
28. Zou CP Clifford JL, Xu XC et al. Modulation of retinoic acid of squamous cell differentiation, cellular RA-binding proteins and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res 1994; 54: 5479-87
29. Joiakim AP, Chopra DP. Retinoic acid and calcium regulation of p53. transforming growth factor beta, and transforming growth factor alpha gene expression and growth in adenovirus-12-SV4Ü transformed human trachéal gland epithelial cells. Am J Res Cell Mol Bio/ 1993: 8: 408-16
30. Navone NM. Tronoco P, Pisters LL et al p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J .Vflt Cancer Insl 1993: 85: 1657-69
31. Kastan MB. Oneykwereb 0, Sidransky D. Vogelstein B. Graig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991: 52: 6304-11
32. Dulic V, Kaufmann KW. Wilson SJ et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced Gl arrest. Cell 1994: 76: 1013-23
33. Biard DSF, Martin M. Le Chun Y et al Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res 1994: 54: 3361-4
34. Kwok T. Mok CH, Menton-Brennan L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res 1994; 54: 2834-6
35. Gotlieb WH. Watson JM, Rezai A. Johnson M. Martinezmaza 0. Berek JS. Cytokine-induced modulation of tumour suppressor gene expression in ovarian cancer cells: upregulation of p53 gene expression and inhibition of apoptosis by tumour necrosis factor alpha. Am J Obst Gijnecol 1994: 170: 1121-30
36. Paquette RL. Lee YY, Wilczynski SP ft al. Mutations of p53 and human papillomavirus infection in carcinoma. Cancer 1993: 72: 1262-80
37. Fakhazadeh SS. Trusko SP. George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumour cell line. EMBO 1991: 10: 1565-9
38. Hussain RF. Nouri AME, Oliver RTD. A new approach for measurement of cytotoxicity using colorimetric assay. ImmimolMeth 1993: 160: 89-96
39. Bartkova }. Bartek J. Lukas J ft al. p53 protein alteration in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer 1991; 49: 196-202
40. Mellon K. Thompson S, Charlton RG ft al. p53. cerb-2 and epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992: 147: 496-9
41. Effert P. Neubauer A. Walter P, Liu E. Alteration of the p53 gene are associated with the progression of a human prostate carcinoma. J Urol 1992: 147: 789-93
42. Thompson SJ. Mellon K. Charlton RG. Marsh C, Robinson M. Neal DE. p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br }Urol 1992: 69: 609-13
43. Serth J. Kuczyk M, Bokemeyer C, Hervatin C. Nafe R. Tan H. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995: 71: 201-5
44. Lamm DL. Bacillus Calmette-Guerin in the therapy of bladder cancer. J Urol 1985; 134: 40-7
45. Tilkin AF. Lubin R. Soussi T ft al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur ] Immunol 1995: 25: 1765-9
46. Hald J, Rasmussen N. Claesson MH. In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immnnol Immnnotherapii 1994: 39: 383-90
47. Stuber G, Leder GH, Storkus WJ et al Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell-line assay and a novel major histocopatibility complex class I-peptide binding assay. Eur J Immunol 1994: 24: 765-8
48. Brown CR, Doxsey SJ, White E, Welch WJ. Both viral (adenovirus Elb) and cellular (HSP-70, p53) components interact with centrosomes. J Cell Physiol 1994; 160: 47-60
49. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci 1992; 15: 3439-42
50. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P. Cytotoxic effects of adeno-virus mediated wild type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1995; 1: 889-97
51. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells by adenovirus-mediated transfer of wild type p53 gene. Cancer Res 1994; 54: 2287-91
52. Nabel E, Nabel D, Yang Z et al Gene transfer in vitro with DNA-Liposome complexes: Lack of autoimmunity and gonadal localisation. Hum Gene Therapy 1992; 3: 649-56
53. Oliver R. Testicular cancer. Current Opinion Oncol 1994; 6: 285-91